SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCANewsfile Corp • 06/06/21
Verrica's VP-102 Application Review for Molluscum Contagiosum Delayed till SeptemberBenzinga • 05/28/21
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum ContagiosumGlobeNewsWire • 05/28/21
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/26/21
Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/12/21
Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/21
Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in JapanGlobeNewsWire • 03/17/21
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial ResultsGlobeNewsWire • 03/04/21
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences ConferenceGlobeNewsWire • 03/03/21
Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care ConferenceGlobeNewsWire • 02/23/21
Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum ContagiosumGlobeNewsWire • 02/17/21
Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology ConferenceGlobeNewsWire • 01/19/21
Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in MolluscumGlobeNewsWire • 11/17/20
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare ConferenceGlobeNewsWire • 11/12/20
Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)GlobeNewsWire • 11/10/20
JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) TrialsGlobeNewsWire • 09/23/20
VRCA Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Verrica Pharmaceuticals Inc. and Lead Plaintiff Deadline: September 14, 2020PRNewsWire • 09/14/20
DEADLINE TODAY: The Schall Law Firm Announces It Is Investigating Claims Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmBusiness Wire • 09/14/20
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc.Business Wire • 09/11/20
DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 09/11/20
VRCA Class Action Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Verrica Pharmaceuticals Inc. and Lead Plaintiff Deadline: September 14, 2020Newsfile Corp • 09/10/20
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc.PRNewsWire • 09/10/20
